ACPE UAN #: 0233-0000-20-041-H04-P
Release Date: October 20, 2020
Expiration Date: October 20, 2023
Activity Type: Knowledge-based
Contact Hours: 1
Activity Fee: Member: $15 Non-Member: $30
Target Audience: Pharmacists who practice in managed care settings.
The first gene therapies for hemophilia A and B are expected to reach the market by 2022, with more projected in the coming years. Proactive development and implementation of risk assessment and mitigation strategies can assist in identifying the appropriate patient populations for gene therapy. But what are the long-term economic and clinical impacts of these therapies in managed care?
This session will discuss key factors managed care pharmacists should consider as therapeutic options for hemophilia diversify. It will outline the advantages and challenges of this therapeutic mechanism within the real-world hemophilia patient population, compare products in the development pipeline, examine cost management strategies, and discuss perspectives on value.
At the completion of this activity, participants should be able to:
- Describe the hemophilia gene therapy product pipeline and recognize factors that affect the safety, efficacy, and durability of gene therapy.
- Illustrate cost management strategies, including the potential for cost offsets based on the efficacy and durability of gene therapies in hemophilia.
- Assess the value of gene therapy for hemophilia from multiple perspectives.
Schedule of Educational Activity:
This activity consists of an audio recording, pre-test assessment questions (not required to pass to continue), post-test questions (required to pass with a score of 70% or higher), and a specific activity evaluation.
The Academy of Managed Care Pharmacy (AMCP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
As an accredited provider, AMCP strictly adheres to the ACPE Standards for Commercial Support and other relevant guidelines and standards to ensure the independence of continuing pharmacy education (CPE) activities. AMCP intends that all CPE activities be independent, objective, balanced, evidence-based, and free of any commercial bias.
Participants should claim CPE credit for this home study activity only if they have not claimed credit for the live activity presented at AMCP Nexus 2020 Virtual.
CPE credit will be processed through the AMCP Learn portal and reported directly to CPE Monitor. Please allow 72 hours for processing and posting in your National Association of Boards of Pharmacy (NABP) e-Profile account.
To receive credit for a home study activity you must:
- Review the full content of the home study activity.
- Complete the post-test and achieve a score of 70% or higher.
- Complete a specific activity evaluation.
System Technical Requirements/Viewing Requirements:
Courses and continuing education activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating websites. View the minimum technical and system requirements for all continuing education activities.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE UAN #0233-0000-20-041-H04-P||1 Contact Hour||October 20, 2020 - October 20, 2023|